- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Direxion Daily S&P Biotech Bull 3X Shares(LABU)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LABU
11/20/2026: LABU (1-star) is currently NOT-A-BUY. Pass it for now.
LABU provides triple daily leveraged exposure to the S&P Biotechnology Select Industry Index via financial derivatives. Its primary strengths lie in its high liquidity, tight trading spreads, and dominance among tactical trading products. It serves as an aggressive tool for short-term momentum strategies rather than a long-term core holding. Key risks include severe compounding decay over time, high expense ratios, and extreme sector volatility driven by binary clinical events. It suits active traders who closely monitor positions and manage risk on a daily basis.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | Due to daily rebalancing and leverage decay, it is unsuitable for long-term growth investing. |
| Momentum investor | Strong fit while signal remains positive | It offers aggressive triple exposure ideal for short-term tactical momentum plays during strong sector rallies. |
| Value investor | Weak fit | Leveraged synthetic exposure ignores traditional fundamental valuation and long-term holding principles. |
| Dividend/Income investor | Weak fit | The fund does not distribute meaningful dividends and focuses purely on daily capital movement. |
| Low-risk investor | Weak fit | The extreme volatility and risk of total capital loss conflict entirely with conservative objectives. |
Investor Profile
Ideal Investor Profile
Active tactical traders, day traders, and sophisticated momentum investors looking for short-term, high-beta exposure to the biotechnology sector.
Suitability
Strictly suited for short-term intraday or multi-day trading, entirely unsuited for buy-and-hold long-term investing due to volatility decay.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Daily 3x leverage amplifies underlying biotech stock fluctuations into extreme portfolio swings. |
| Market risk | High | The biotech sector is inherently speculative and heavily impacted by clinical data and regulatory decisions. |
| Concentration | High | The fund targets a single industry sector, exposing investors to localized structural downturns. |
| Tracking/expense | Medium / high | Compounding and high expense ratios cause long-term performance to deviate significantly from 3x the index. |
| Liquidity | Low | Despite strong fund-level trading volume, underlying constituent liquidity can strain severe market events. |
| Business/sector quality | High | Many constituents are pre-revenue clinical-stage companies carrying binary operational risks. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
LABU exhibits exceptionally high historical volatility due to its 3x daily leverage multiplier applied to an already volatile biotech index.
Market Risk
Carries acute exposure to adverse clinical updates, regulatory changes, and broader risk-off equity corrections.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | S&P Biotechnology Select Industry Index — seeks 3x daily leverage return | 100 | Provides triple daily leveraged exposure to the performance of the US biotech sector index through swap agreements and financial derivatives. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type ETF | Historic Profit -3.61% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

